HAMBURG, GERMANY / ACCESSWIRE / April 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, the systems were shut down proactively and disconnected from the Internet to secure from data corruption or breaches. The IT systems are currently being examined and the scope of the impact is being reviewed. Highest diligence will be applied to data integrity.
- End of the ad hoc release -
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.31 |
| Daily Change: | -0.23 -5.07 |
| Daily Volume: | 28,720 |
| Market Cap: | US$12.340M |
December 11, 2024 November 06, 2024 October 23, 2024 September 26, 2024 September 05, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
